Tempest Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Tempest Therapeutics, Inc. (TPST) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $478.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-30
- Tempest Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $478.00K, a 57.92% decline from fiscal 2024.
- Tempest Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $1.14M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2025-12-31 | $478.00K 10-K · filed 2026-03-30 |
| 2024-12-31 | $1.14M 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |